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Abstract  
Background: Despite ACC/AHA guidelines indicating implantable cardioverter defibrillator 
(ICD) as  class  I  therapy for  primary  prevention  of  sudden cardiac  death in patients  with 
EF≤35%, ICD  utilization rates in real world practice have been low.                       
Objective: To determine the rate of ICD implantation at a tertiary care academic center and to 
assess  the  reasons  for  under-utilization  of  the  same.                                
Methods: Review of a prospectively collected database which included all patients diagnosed 
with  an  EF≤35%  was  performed  to  assess  the  rate  of  ICD  implantation  and  mortality. 
Reasons for non-implantation of ICD were then assessed from detailed chart review.       
Results:  A total  of  707 patients  (age  69.4 ±  14.1 years)  with  mean EF of  26±7% were 
analyzed. Only 28% (200/707) of patients had ICDs implanted. Mortality was lower in the 
group with ICD (25% vs 37%, p=0.004).  When patients  who either  died or  were lost  to 
follow-up prior to 2005 were excluded, ICD utilization rate was still low at 37.6%. The most 
common reason for non-implantation of ICD was physicians not discussing this option with 
their  patients.  Patient  refusal  was  the  second most  common reason.                    
Conclusions: ICD  Implantation  rates  for  primary  prevention  of  SCD  in  patients  with 
EF≤35%  is  low.  Physician  and  patient  education  should  be  addressed  to  improve  the 
utilization  rates.                                         
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Background
Heart Failure is a major public health problem affecting more than 5 million people in the 
United States with 550,000 new cases diagnosed annually and 57,000 deaths annually [1,2]. 
Mortality rates from the Framingham population study are over 25% at 1 year and 50% at 5 
years after the onset of heart failure [2]. The two main causes of death in patients with heart 
failure  are  progressive  heart  failure  and sudden cardiac  death  (SCD).                   
Consequently,  the  2005  ACC/AHA/ECS  heart  failure  guidelines  and  the  2009  update 
recommend optimum medical management with beta-blockers (BB), angiotensin-converting 
enzyme  inhibitors  (ACE)  or  angiotensin  receptor  blockers  (ARB),  and  aldosterone 
antagonists (AA) as Class I therapies to prevent progression of HF and to improve survival. 
These guidelines also recommend an implantable cardioverter defibrillator (ICD) as a Class I 
indication for the primary prevention of sudden cardiac death (SCD) in patients with ischemic 
and non-ischemic cardiomyopathy with an EF < 35%  with NYHA class II and III (Class IIa 
for EF between 30-35% per 2005 guidelines which is now a class I indication) [3,4]. These 
guidelines  are  based  on  several  randomized  control  trials  including  MADIT-  I  and  II, 
MUSTT  and  SCDHeFT  [5-8].                                       
While these randomized clinical trials have shown survival benefit of ICD's in patients with 
left ventricular systolic dysfunction, the utilization rate of ICD's for primary prevention of 
SCD in real world practice has remained suboptimal and varies greatly from less than 20% to 
40% [9-12]. Only a small number of hospitals across the United States have ICD implantation 
rates above 50% for eligible patients [9]. While gender and racial  disparities and hospital 
level variations have been described, the reasons for underutilization of ICD's from a clinical 
stand point are largely unknown. In this study we report the rates of ICD implantation and 
medical management in patients with left ventricular systolic dysfunction with EF≤ 35% at a 
large academic medical center and evaluate the reasons for underutilization.                  
Methods
This  is  a  retrospective  study of  a  large  observational  study derived from a prospectively 
collected Cardiovascular Database at the University of Kansas Hospital,  Kansas City, KS. 
This is a tertiary care referral center for the Midwestern region with a large cardiovascular 
program  including  state  of  the  art  electrophysiology  laboratories  and  five 
electrophysiologists.
Study  population                                      
The study population included all patients who were diagnosed with left ventricular ejection 
fraction  (LVEF)  ≤  35% between  1998  and  2006.  A  low EF  documented  by  any  of  the 
imaging  modalities  including  echocardiogram,  nuclear  imaging,  cardiac  computer 
tomographic  angiography  or  magnetic  resonance  imaging  or  ventriculography  were 
considered appropriate for the study. Cardiovascular database, electronic medical records and 
paper charts of these patients were reviewed by two investigators after obtaining approval 
from  the  institutional  review  board.  The  conduct  of  the  study  was  overseen  within  the 
regulatory guidelines of HIPAA. Three consecutive EFs were extracted for each patient. If 
there was a sudden change in EFs in a 6 month period, accuracy of EFs were evaluated by 
reviewing  the  actual  imaging  study.  The  oldest  LVEF  ≤35% was  included  in  the  study 
analysis. Each patient was followed until May 2009. Patients who spontaneously improved 
their EF within 1 year were excluded from the study. Patients who had an improvement in EF 
beyond 1 year were also noted. For analysis of mortality, all patients were included but for 
purposes of ICD implantation analysis, all patients who died or were lost to follow-up prior to 
and including year 2005 were excluded.  This is because guidelines reporting implantation of 
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ICDs  for  primary  prevention  in  ischemic  and  non-ischemic  patients  with  EF<35%  was 
reported only in 2005 after the SCD-Heft trial.  Prior to that, ICDs were indicated only in 
ischemic cardiomyopathy patents with EF< 30% per the 2002 device therapy guidelines as a 
class IIa recommendation. Baseline demographic variables and clinical variables along with 
medical treatment received with BBs, ACEIs, ARBs, AA and ICDs were also noted. Time to 
ICD implantation  was considered  from the  earliest  date  when EF≤ 35 % was recorded.   
Mortality records were obtained from social security death index.                          
Assessing reasons for  non implantation  of  ICDs                                     
Records were manually reviewed by 2 independent investigators to identify the reasons why 
an ICD was not implanted. All patients who had an EF ≤35% for at least one year from the 
initial diagnosis of LV dysfunction and were still alive and following with the clinics were 
assessed for reasons why an ICD was not implanted. All cardiology clinic encounters were 
reviewed  and  any  mention  of  ICD  implantation  by  the  cardiologist  was  considered  as 
discussed.  If  there  was  no  documentation  about  ICD  in  any  of  the  encounters,  it  was 
considered that the cardiologist had not discussed it.  However, if specific reasons such as 
significant comorbidities or patient refusal were cited for non-implantation of ICDs they were 
accordingly noted. Patients who had a single or dual chamber pacemaker but no ICD were 
also reviewed for  documentation  of  a  discussion regarding ICD upgrade.                
Statistical  analysis                                       
Rates of ICD implantation and medical  treatment  received were expressed as percentages 
while continuous data was expressed as mean ± SD. Student t tests were used to compare 
continuous  variables  while  Chi-square  and  Exact  tests  were  used  to  compare  discrete 
variables. A p value less than 0.05 was considered significant. Kaplan-Meier survival curves 
were obtained  for  patients  with  and without  ICD implantation.  Cox proportional  hazards 
model  with forward model  was used to  identify  univariate  and multivariate  predictors  of 
mortality. Logistic regression analysis was used to identify predictors of ICD implantation. 
Reasons for ICD non-utilization were all analyzed after excluding patients who died or were 
lost to follow up prior to 2005 and noted in percentages. SAS version 9.1.3 (SAS Institute 
Inc,  Cary,  NC)  was  used  for  the  analyses.                                         
Results
A total  of 707 patients (age 69.4 ± 14.1 years) with an EF ≤ 35% met inclusion criteria. 
Echocardiogram was the most common method utilized for EF measurement (84% patients) 
followed by thallium stress test, ventriculogram and multigated nuclear scan (MUGA). Mean 
EF was 26±7%. NYHA (New York Heart Association) class 1, 2, 3 and 4 were seen in 30%, 
40%,  26%  and  4%  of  patients  respectively.  Mean  QRS  duration  was  125±36  ms.  The 
majority  of  patients  were  males  (66%)  and  of  Caucasian  race  (80%).  Ischemic 
cardiomyopathy was seen in 59% of patients while 41% had non-ischemic cardiomyopathy. 
Mean  duration  of  cardiomyopathy  (LV  dysfunction)  was  76±21  months.  Percentages  of 
patients on ASA, BB and ACE/ARB were 80%, 81% and 75% respectively at 1 year of heart 
failure  diagnosis.  AA,  digoxin  and statins  were  used  in  24%,  50% and 68% of  patients 
respectively. Eighty percent were on diuretics. ICDs were implanted in only 28% of  patients 
(n = 200/707). There was a significant difference in all cause mortality between HF patients 
with ICDs compared to those without (25% vs 37%, p=0.004). Figure 1 shows Kaplan-Meier 
survival curves for patients with and without ICD. Age (HR 1.02, CI 1.01-1.03 p<0.0001), 
absence of ICD (HR 1.5, CI 1.1-2, p=0 .04), lower EF (HR 3.4, CI 1.6-10, p=0.04), and 
NYHA  class  (HR  1.7,  CI  1.2-2.3,  p=0.001)  were  found  to  be  significant  predictors  of 
mortality  on  multivariate  analysis.                                  
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Figure 1: Kaplan Meir Survival Curves (in months) for Patients with ICD (1) and Without ICD (2).        
Since  the  guidelines  recommended  ICD therapy for  primary  prevention  for  patients  with 
ischemic and non ischemic cardiomyopathy with EF<35% only in 2005, for purposes of ICD 
implantation assessment, all patients who died prior to December 2005 (n=72 with 64 in non-
ICD group and 8 in ICD group) and patients who were lost to follow-up prior to December 
2005 (n=125) were excluded. The effective sample size was thus 510 patients.                   
The  ACC/AHA 2002  guidelines  do  indicate  ICD implantation  in  patients  with  ischemic 
cardiomyopathy with EF <30% as class IIa indication. Accordingly, of the 64 patients who 
died prior to 2005 in the no-ICD group,   36% of them qualified for ICD implantation. A 
considerable proportion of patients (n=125) were lost to follow-up as the University hospital 
is a tertiary referral center and patients were admitted for procedures and acute events with 
follow up in clinics  once or twice and were then lost to follow-up.                      
Of the 510 patients who were alive after 2005, the percentage of patients with an ICD was 
37.6% (192/510). Baseline demographic and clinical characteristics of these patients with and 
without an ICD are represented in  Table 1. In patients who had an ICD implanted,  mean 
duration between diagnosis and implantation was 2.9±2.1 years. These patients had higher 
body  mass  index,  longer  QRS  interval  and  were  on  optimal  medical  management  (BB, 
ACE/ARB, AA and statins) compared to those without an ICD. Univariate predictors of ICD 
implantation included presence of BB, ACE/ARB, diuretic, AA , statins and higher QRS. On 
multivariate analysis, presence of ACE inhibitors/ARB (OR 2, CI 1.2-3.4, p=0.04) and AA 
(OR 1.9, CI 1.3-3, p=0.001) were found to be the only predictors of ICD implantation. Of 
those  patients  who  had  an  ICD,  48% of  patients  had  cardiac  resynchronization  therapy-
defibrillator  (CRT-D),  31% of patients  had a  dual  chamber ICD while  21% had a single 
chamber ICD. Patients without an ICD had pacemakers in 19.7% including CRT-pacemaker in 3% 
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Table 1: Baseline demographic and clinical variables.                                     
Of the total of 510 patients, 62.3% of patients did not have an ICD implantation and reasons 
for non-utilization of ICD were assessed. The biggest reason for non implantation was that no 
discussion  took  place  between  the  cardiologist  and  patient  regarding  the  option  of  ICD 
placement (23.2% of cases). While the option was discussed in other cases, 22.6% of patients 
refused an ICD implant. In another 16.3% of patients, EF spontaneously improved to >35% 
more than a year later. Patients in NYHA class 1 contribute to 7.9% of patients. About 5.7% 
of patients were lost to follow-up after 2005 and 0.3% of patients died within one year of 
diagnosis before an ICD was discussed or implanted. Patients who died after more than a year 
after diagnosis of low EF were not included in this group, instead the other reasons why an 
ICD was not implanted in this group was ascertained and included in that category. Expected 
survival of less than a year like those who had end stage cancer were stated as reasons for 
ICD non implantation in 3.8% of patients. Similarly, low quality of life including dementia,  
psychiatric reasons was present 3.1% of patients. Comorbidities including COPD and obesity 
precluding ICD placement were observed in 1.9%. In another 4.7% of patients the option of 
ICD was discussed but not implanted. Either the patient died before an ICD was placed or had 
not followed up (1.8%). In other cases, the physician has not followed up on it at further 
clinic visits (2.8%) or discussed most recent visits (Table 2). In 9% of cases, miscellaneous 
reasons were cited such as an expected improvement in EF, or occluded bilateral subclavian 
vessels  which  precluded  ICD  implantation.  This  also  included  situations  where  ICD 
placement was deferred until treatment of co-existent medical conditions such as cancer or 
osteomyelitis were completed. Thus, in 44% of patients ICD implantation was discussed or 
considered even if  the patients  refused in  22% of cases.  While  all  patients  were seen by 
cardiologists,  25% of  them  were  also  seen  by  an  electrophysiologist  and  23% of  those 
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encounters  included  discussion  about  ICD  placement.                          
Table 2: Reasons for non-utilization of ICD therapy (n=318)                              
Discussion
Our study showed that only one third of patients with EF≤35% received an ICD for primary 
prevention of SCD. While optimal medical treatment with BB, ACE/ARB, diuretics and AA 
was close to goal even though not at 100%, ICD implantation rates for primary prevention of 
SCD were low. Our study identified the reasons for non-implantation of ICD with the most 
common  being  the  physician  not  discussing  the  option  of  ICD placement.  As  expected, 
mortality in patients without the ICD was higher than those with ICD.                   
Mortality in our study was defined as all-cause mortality and it is unknown if most of these 
deaths were due to sudden cardiac death. It is possible that of the 9% (n=64) of patients who 
died prior to 2005 without an ICD some of them  could have died of arrhythmic causes. 
Mortality  was  significantly  higher  in  patients  without  an  ICD after  controlling  for  other 
factors  including  NYHA  class.                                     
Our study findings on medical  management  of heart  failure are similar  to those found in 
previous heart failure studies [13-15]. Efficacy of BB, ACEIs/ARBs and AA in HF has been 
well established [16-19] and >75% of patients in our study were on BB, ACE/ARB and ASA. 
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Utilization rates for AA were low but only 30% of patients in our study had NYHA class III 
and IV symptoms which explains  the small  percentage.                                 
 
 ICDs have also been shown to be cost effective [20]. However, the utilization rate of ICDs in 
patients with left ventricular dysfunction in our study and other studies has been poor [9-
12,21]. In a recent study utilizing data from the Get-With the Guidelines data, hospital level 
variations were noted with rates as low as tertile of 1% to as high as 35% with an overall rate 
of  20%  [9].                                                     
The reasons for the low rates of implantation were not described. Also, that study assessed the 
rates of implantation at discharge or plans for ICD placement following discharge and thus 
may not be an accurate representation of actual ICD placement. Patients with recent MI who 
may qualify for an ICD after 40 days may be lost to follow-up. Our study in contrast captures 
patients in an outpatient setting where patients are regularly followed up and the results are 
derived from the community rather than trial population. Some of the other studies evaluated 
gender and racial disparities in ICD implantation for primary and secondary prevention. Our 
study is different in that we assessed the reasons for non-implantation of ICD in ICD eligible 
primary prevention patients. There were no differences in race and gender in our study as 
suggested by previous trials [10-12]. Among patients who received an ICD in our population, 
the majority received it for primary prevention (96.7%). 45% of these were CRT-D devices 
and the rest were single chamber and dual chamber ICD's. Patients with ICD were also on 
higher rates of ACE/ARB, BB, AA and statins. It is also possible that patients considered for 
ICD implantation were first initiated on maximal medical management before an ICD was 
placed. It is also possible that these patients represent a select group who are compliant with 
their medications and thus considered further for an ICD. Patients with atrial fibrillation (AF) 
had a trend towards higher rate of ICD implantation. It is possible that patients with AF were 
referred to electrophysiologists who would have facilitated ICD placement. It is also possible 
that these patients had severe symptomatic cardiomyopathy causing atrial fibrillation and the 
more symptomatic patients were considered for an ICD implant.                                 
Extensive  review of  the  patient  charts  reveal  that  the  absence  of  any kind of  discussion 
regarding an ICD by the primary cardiologist to be the most common reason behind non ICD 
implantation in patients who otherwise met criteria for primary prevention ICD therapy. This 
observation opens up many speculative reasons for the physician's inability to address the 
need for an ICD. The physician may be unaware of the recent guidelines for heart failure 
management  especially  if  the  patient  is  being  followed  by  a  non-cardiologist.  While 
maximizing medical therapy the issue of ICD may be deferred and never returns to discussion 
during follow up.  It is also possible that cardiologists do not think of primary prevention with 
ICD therapy if patients presenting to their clinic are doing well symptomatically. Another 
barrier to ICD implantation may be the cost of the device. Other reasons for patients' refusal 
of ICD therapy could be the fear of being shocked, unawareness of the importance of ICD, or 
cultural  differences in the perceptive needs for therapy.                                  
A recent study by Al-khatib et al [22] contrasts completely from our study findings. ICD use 
at  their  institution  was  higher  (60%).  While  this  could  represent  institutional  differences 
certain  other  factors  listed  below  also  could  also  have  accounted  for  the  differences  in 
implantation rates. Their study population included all patients admitted to the hospital over a 
6 month period alone. Our study is all inclusive of patients with low EF and not necessarily 
only patients admitted with heart failure to the hospital. Their study only included patients 
with EF<30% while ours considered everyone with EF< 35%. Their  study only discusses 
percentage of patients who met criteria but had no ICD, ours goes a step further to assess if 
the ICD was ever recommended by the physician.                                       
Our  study  demonstrates  several  important  findings.  The  utilization  rate  of  ICDs  in  HF 
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patients even in a large academic center with readily available quality cardiovascular care is 
suboptimal. Among patients with no ICD, the option was actually considered or discussed by 
physicians in 44% of patients even if the patients refused or had co-morbidities precluding 
implantation. Since another 22% either died or lost to follow-up or had improved their EF, 
attention should be directed to the remaining 24% of subjects where the option was never 
discussed.  This  can  be  achieved  by  targeting  educational  interventions  towards  the 
physicians. Likewise, patient refusal of the device was another major cause and interventions 
that  increase  patient  awareness  regarding  the  survival  benefit  of  these  devices  may  help 
greatly.  When  patients  had  refused  an  ICD  device,  there  were  no  further  discussions 
regarding ICD placement at subsequent visits. We believe that reinforcing the need for ICD 
placement  at  multiple  visits  may  convince  patients  of  its  benefits.              
Our study confirms that ICD implantation rates are not at goal and interventions should be 
targeted  towards improving these rates.  This can be done by using pop-ups in  electronic 
medical  records  on  patients  with  heart  failure.  Patients  who  refuse  an  ICD  should  be 
counseled  at  every  visit  and  the  pros  and  cons  of  ICD  placement  should  be  discussed. 
Another alternative is to refer to the heart failure clinic where a physician and/or a nurse 
practitioner  would explain  to  the patient  in  detail  about  the benefits  of  ICD. Educational 
interventions and current performance awareness may ultimately help in improving the rates 
for  ICD  implantation  for  primary  prevention.                                    
Study  limitations                                    
This is  a retrospective study at  a single institution.  Nevertheless  this  is  a tertiary  referral 
center with 30 cardiologists and an active electrophysiology program. It was assumed that 
ICD discussion did not take place if it  was not documented in the medical record. Some 
selection bias may have been present since majority of patients were of Caucasian race. All-
cause mortality and not cardiovascular mortality was recorded, so the exact cause of death in 
patients  without  an  ICD  are  unknown.                                      
Future  studies                                        
Oftentimes patients go through a chain of screening starting with the primary care physician, 
through a cardiologist and finally the electrophysiologist. It will be important to identify the 
origination of the recommendation for ICD therapy in the chain of decision making so as to 
determine  targets  for  educational  interventions.                                 
Conclusions
This study suggests that the use of ICDs in patients with left ventricular systolic dysfunction 
is less than optimal and  identifies the areas that need attention namely, physician discussion 
and reinforcement with the patient about ICD implantation and patient education about the 
benefits  of  the  device.                                            
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